Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 28, 2026Journal of Coronary Artery DiseaseOpen Access

Lipoprotein(a)

View Full Paper
Ask AI
Bookmark
Share

Key result

Emerging RNA-targeted therapies substantially lower causal CVD risk factor Lp(a) pending ongoing outcome trials.

Why the study?

Lipoprotein(a) is a genetically determined lipoprotein recognized as an independent and causal risk factor for ASCVD and other cardiovascular diseases, but challenges remain in measurement and therapeutic targeting.

Design

Review article

Authors

YTYasuaki TakejiHTHayato TadaMTMasayuki Takamura

Discussion

Loading...

Member takes

Overview

Lp(a) lowering remains investigational in high-risk patients; leaves open whether RNA-targeted therapies improve cardiovascular outcomes pending definitive trials.

Key Points

  • To review the genetics, pathophysiology, measurement challenges, and emerging therapeutic strategies concerning lipoprotein(a) in cardiovascular disease.
  • Synthesized epidemiological and genetic evidence assessing lipoprotein(a) [Lp(a)] levels and cardiovascular risk across diverse cohorts.
  • Evaluated particle structure, kringle IV type 2 repeat polymorphism size heterogeneity, and clinical assay biases.
  • Reviewed biological mechanisms of disease and evidence from clinical trials of RNA-targeted therapies.
  • Lp(a) is an independent, causal risk factor for atherosclerotic cardiovascular disease and aortic stenosis via atherogenesis, oxidized phospholipid-driven inflammation, and antifibrinolytic activity.
  • Considerable interindividual variation in circulating levels arises from apolipoprotein(a) isoform size heterogeneity, creating difficulties with assay standardization and reporting units.
  • Novel RNA-targeted therapeutics, including antisense oligonucleotides and small interfering RNA, achieve substantial reductions in Lp(a) levels, with definitive cardiovascular outcome trials underway.

PICO

P
Population
Atherosclerotic cardiovascular disease (ASCVD) and elevated Lipoprotein(a)
I
Intervention / Comparator
Lipoprotein(a) targeted therapies

Lp(a) is a causal risk factor for cardiovascular disease and a promising therapeutic target, with ongoing trials evaluating the clinical benefit of novel RNA-targeted therapies.

Limitations

  • Measurement of Lp(a) remains challenging due to assay variability, isoform-dependent bias, and differences in reporting units.
  • Whether substantial reductions in Lp(a) levels will lead to a reduction in cardiovascular events remains unknown pending ongoing large-scale outcome trials.

Cite This Study

Takeji et al. (2026) conducted a review in Atherosclerotic cardiovascular disease (ASCVD) and elevated Lipoprotein(a). Lipoprotein(a) targeted therapies was evaluated. Elevated Lipoprotein(a) is a causal risk factor for cardiovascular disease, and emerging RNA-targeted therapies have demonstrated substantial reductions in Lp(a) levels, pending ongoing outcome trials.

synapsesocial.com/papers/6ab9b47e7822ec8fc3d8e2fdhttps://doi.org/10.7793/jcad.32.007
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Lipoprotein(a) and Atherosclerotic Cardiovascular Disease: Where Do We Stand?2024 · 30 citations
  2. 2Lipoprotein(a): a risk factor for atherosclerosis and an emerging therapeutic target2022 · 61 citations
  3. 3Lp(a) in the Horizon of Diagnostics and Therapy2025 · 2 citations
  4. 4Lipoprotein(a) in clinical practice: Risk stratification and therapeutic strategies2025 · 6 citations
  5. 5Elevated Lp(a): Guidance for Identifying and Managing Patients2024 · 2 citations